Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs.

Heiniö C, Sorsa S, Siurala M, Grönberg-Vähä-Koskela S, Havunen R, Haavisto E, Koski A, Hemminki O, Zafar S, Cervera-Carrascon V, Munaro E, Kanerva A, Hemminki A.

Hum Gene Ther. 2019 Jun;30(6):740-752. doi: 10.1089/hum.2018.240. Epub 2019 Feb 28.

PMID:
30672366
2.

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.

Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21.

3.

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.

Zafar S, Sorsa S, Siurala M, Hemminki O, Havunen R, Cervera-Carrascon V, Santos JM, Wang H, Lieber A, De Gruijl T, Kanerva A, Hemminki A.

Oncoimmunology. 2018 Aug 15;7(10):e1490856. doi: 10.1080/2162402X.2018.1490856. eCollection 2018.

PMID:
30386680
4.

Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, Anttila M, Kanerva A, Hemminki A.

Mol Ther. 2018 Sep 5;26(9):2243-2254. doi: 10.1016/j.ymthe.2018.06.001. Epub 2018 Jul 13.

PMID:
30017877
5.

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A.

Oncoimmunology. 2018 Apr 9;7(5):e1412902. doi: 10.1080/2162402X.2017.1412902. eCollection 2018.

6.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.

JCI Insight. 2018 Apr 5;3(7). pii: 99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5.

7.

Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.

Santos JM, Havunen R, Siurala M, Cervera-Carrascon V, Tähtinen S, Sorsa S, Anttila M, Karell P, Kanerva A, Hemminki A.

Int J Cancer. 2017 Oct 1;141(7):1458-1468. doi: 10.1002/ijc.30839. Epub 2017 Jun 29.

8.

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.

Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karell P, Rusanen J, Nettelbeck DM, Ehrhardt A, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2016 Dec 31;4:77-86. doi: 10.1016/j.omto.2016.12.004. eCollection 2017 Mar 17.

9.

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.

Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tähtinen S, Bramante S, Vassilev L, Wang H, Lieber A, Hemmi S, de Gruijl T, Kanerva A, Hemminki A.

Oncoimmunology. 2016 Dec 7;6(2):e1265717. doi: 10.1080/2162402X.2016.1265717. eCollection 2017.

10.

Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Nov;24(11):2033. doi: 10.1038/mt.2016.196. No abstract available.

11.

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.

Tähtinen S, Blattner C, Vähä-Koskela M, Saha D, Siurala M, Parviainen S, Utikal J, Kanerva A, Umansky V, Hemminki A.

J Immunother. 2016 Nov/Dec;39(9):343-354.

PMID:
27741089
12.

Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.

Siurala M, Vähä-Koskela M, Havunen R, Tähtinen S, Bramante S, Parviainen S, Mathis JM, Kanerva A, Hemminki A.

Oncoimmunology. 2016 Feb 18;5(5):e1136046. doi: 10.1080/2162402X.2015.1136046. eCollection 2016 May.

13.

Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Erratum in: Mol Ther. 2016 Nov;24(11):2033.

14.

Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.

Bramante S, Koski A, Liikanen I, Vassilev L, Oksanen M, Siurala M, Heiskanen R, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A.

Oncoimmunology. 2015 Aug 27;5(2):e1078057. eCollection 2016 Feb.

15.

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

Tähtinen S, Grönberg-Vähä-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M, Hemminki A.

Cancer Immunol Res. 2015 Aug;3(8):915-25. doi: 10.1158/2326-6066.CIR-14-0220-T. Epub 2015 May 14.

16.

GMCSF-armed vaccinia virus induces an antitumor immune response.

Parviainen S, Ahonen M, Diaconu I, Kipar A, Siurala M, Vähä-Koskela M, Kanerva A, Cerullo V, Hemminki A.

Int J Cancer. 2015 Mar 1;136(5):1065-72. doi: 10.1002/ijc.29068. Epub 2014 Jul 10.

17.

Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.

Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vähä-Koskela M, Hemminki A.

Int J Cancer. 2015 Feb 15;136(4):945-54. doi: 10.1002/ijc.29048. Epub 2014 Jul 3.

18.

Gastric cellular turnover and the development of atrophy after 31 years of follow-up: a case-control study.

Moss SF, Valle J, Abdalla AM, Wang S, Siurala M, Sipponen P.

Am J Gastroenterol. 1999 Aug;94(8):2109-14.

PMID:
10445536
19.

Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study.

Valle J, Kekki M, Sipponen P, Ihamäki T, Siurala M.

Scand J Gastroenterol. 1996 Jun;31(6):546-50.

PMID:
8789892
20.

The relationships between chronic gastritis and gastric acid secretion.

Sipponen P, Kekki M, Seppälä K, Siurala M.

Aliment Pharmacol Ther. 1996 Apr;10 Suppl 1:103-18. Review.

PMID:
8730265
21.

Rate of Helicobacter pylori acquisition among Finnish adults: a fifteen year follow-up.

Sipponen P, Kosunen TU, Samloff IM, Heinonen OP, Siurala M.

Scand J Gastroenterol. 1996 Mar;31(3):229-32.

PMID:
8833351
22.

H. pylori corpus gastritis--relation to acid output.

Sipponen P, Hyvärinen H, Siurala M.

J Physiol Pharmacol. 1996 Mar;47(1):151-9.

PMID:
8777295
23.

Helicobacter pylori, gastritis and gastric carcinoma.

Siurala M.

Ann Med. 1995 Jun;27(3):285-6. No abstract available.

PMID:
7546615
24.

Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992.

Sipponen P, Helske T, Järvinen P, Hyvärinen H, Seppälä K, Siurala M.

Gut. 1994 Sep;35(9):1167-71.

26.

Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis.

Karnes WE Jr, Samloff IM, Siurala M, Kekki M, Sipponen P, Kim SW, Walsh JH.

Gastroenterology. 1991 Jul;101(1):167-74.

PMID:
2044906
27.

The Sydney System: epidemiology and natural history of chronic gastritis.

Sipponen P, Kekki M, Siurala M.

J Gastroenterol Hepatol. 1991 May-Jun;6(3):244-51. Review.

PMID:
1912435
28.

Helicobacter pylori and gastritis in children with abdominal complaints.

Maaroos HI, Rägo T, Sipponen P, Siurala M.

Scand J Gastroenterol Suppl. 1991;186:95-9.

PMID:
1759137
29.

What fraction of hospital ulcer patients is eligible for prospective drug trials?

Kääriäinen I, Sipponen P, Siurala M.

Scand J Gastroenterol Suppl. 1991;186:73-6.

PMID:
1759133
30.

Increase of serum pepsinogen I with age in females with normal gastric mucosa but not in males, possibly due to increase in acid-pepsin secreting area.

Kekki M, Samloff IM, Sipponen P, Ihamäki T, Siurala M.

Scand J Gastroenterol Suppl. 1991;186:62-4.

PMID:
1759131
31.

Functional characteristics of duodenal ulcer patients and their first-degree relatives.

Vuoristo M, Pikkarainen P, Samloff IM, Sipponen P, Kekki M, Siurala M.

Scand J Gastroenterol Suppl. 1991;186:52-61.

PMID:
1759129
32.

Helicobacter pylori and duodenal ulcer. A study of duodenal ulcer patients and their first-degree relatives.

Valle J, Pikkarainen P, Vuoristo M, Sipponen P, Kekki M, Siurala M.

Scand J Gastroenterol Suppl. 1991;186:45-51.

PMID:
1759128
33.

Chronic gastritis profiles in sibs of probands calculated to carry a highly increased risk of gastric carcinoma.

Kekki M, Ihamäki T, Varis K, Siurala M.

Scand J Gastroenterol Suppl. 1991;186:29-32.

PMID:
1759125
34.

Enrichment of combined antral and corpus atrophic gastritis ("combined AG") in sibs of gastric carcinoma patients.

Kekki M, Siurala M, Ihamäki T.

Scand J Gastroenterol Suppl. 1991;186:24-8.

PMID:
1759124
35.

Characteristics of gastric mucosa which precede occurrence of gastric malignancy: results of long-term follow-up of three family samples.

Ihamäki T, Sipponen P, Varis K, Kekki M, Siurala M.

Scand J Gastroenterol Suppl. 1991;186:16-23.

PMID:
1759123
36.

The story of gastritis.

Siurala M.

Scand J Gastroenterol Suppl. 1991;186:1-3. No abstract available.

PMID:
1759114
37.

Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients.

Sipponen P, Varis K, Fräki O, Korri UM, Seppälä K, Siurala M.

Scand J Gastroenterol. 1990 Oct;25(10):966-73.

PMID:
2263883
38.

Fasting levels of serum gastrin in different functional and morphologic states of the antrofundal mucosa. An analysis of 860 subjects.

Sipponen P, Valle J, Varis K, Kekki M, Ihamäki T, Siurala M.

Scand J Gastroenterol. 1990 May;25(5):513-9.

PMID:
2359980
39.

Helicobacter (Campylobacter) pylori infestation and the development and progression of chronic gastritis: results of long-term follow-up examinations of a random sample.

Villako K, Maards H, Tammur R, Keevallik R, Peetsalu M, Sipponen P, Kekki M, Siurala M.

Endoscopy. 1990 May;22(3):114-7.

PMID:
2357934
40.

Peptic ulcer and chronic gastritis: their relation to age and sex, and to location of ulcer and gastritis.

Kekki M, Sipponen P, Siurala M, Laszewicz W.

Gastroenterol Clin Biol. 1990;14(3):217-23.

PMID:
2344909
41.

[Helicobacter pylori and chronic gastritis in the gastric biopsy material in a group of randomly selected adult inhabitants of Estonia].

Maaroos KhI, Villako KP, Sipponen P, Kekki M, Siurala M, Tammur RKh, Tamm AO, Savisaar EV, Viĭrsalu VT.

Arkh Patol. 1990;52(10):9-11. Russian.

PMID:
2281981
44.

Gastric ulcer and gastritis: results of short-term follow-up examinations.

Laszewicz W, Gabryelewicz A, Sipponen P, Kekki M, Laxén F, Siurala M.

Hepatogastroenterology. 1987 Dec;34(6):265-8.

PMID:
3428859
45.

Decreased incidences of intestinal and diffuse types of gastric carcinoma in Finland during a 20-year period.

Sipponen P, Järvi O, Kekki M, Siurala M.

Scand J Gastroenterol. 1987 Sep;22(7):865-71.

PMID:
3672044
46.

Gastric ulcer and gastritis. Results of short-term follow-up.

Laszewicz W, Gabryelewicz A, Sipponen P, Kekki M, Siurala M.

Acta Med Pol. 1987;28(1-4):23-34. No abstract available.

PMID:
3506372
47.

Classification principles and genetics of chronic gastritis.

Kekki M, Siurala M, Varis K, Sipponen P, Sistonen P, Nevanlinna HR.

Scand J Gastroenterol Suppl. 1987;141:1-28.

PMID:
3481655
48.

The sequelae and course of chronic gastritis during a 30- to 34-year bioptic follow-up study.

Ihamäki T, Kekki M, Sipponen P, Siurala M.

Scand J Gastroenterol. 1985 May;20(4):485-91.

PMID:
4023614
49.

Hypersecretion of gastric acid in a representative Finnish family sample.

Kekki M, Sipponen P, Siurala M.

Scand J Gastroenterol. 1985 May;20(4):478-84.

PMID:
4023613
50.

Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data.

Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M.

Int J Cancer. 1985 Feb 15;35(2):173-7.

PMID:
3871738

Supplemental Content

Loading ...
Support Center